In the latest Ebola outbreak, a total of 61 cases were recorded and 28 lives were claimed in the Congo region. But now the World Health Organization has reported that the spread of this Ebola outbreak has "largely been contained" after the success of Merck's late-stage vaccination campaign for more than a month.
The U.S, Based Array BioPharma received FDA approval for its much-awaited BRAFTOVI capsules with the combination of MEKTOVI tablets for the treatment of patients with metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
Epidiolex, also known as purified cannabidiol was approved to treat Lennox-Gastaut syndrome and Dravet syndrome specifically in patients aged 2 and older. Both these conditions start during childhood. Recurrent seizures pose a huge risk of death.
The inject is developed to achieve the natural outflow of aqueous humor by making two patent bypasses through the trabecular meshwork, glaucomatous eyes the main source of resistance resulting in multi-directional flow through Schlemm’s canal
Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
The Food and Drug Administration (FDA) has granted approval for a request made by DreaMed regarding their artificial intelligence-enabled diabetic software, which is exclusively meant for the providers, who are managing Type 1 diabetes patients.
A new robotic system called OSCANN Desk has been developed by researchers at Spain’s Universidad Politécnica de Madrid (UPM) and start-up AURA Innotive Robotics. The system has been designed for the accurate analysis of eye movements in order to detect neurodegenerative diseases such as Parkinson’s disease.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.